Thierry Van Nieuwenhove, CEO, joined Quotient Sciences in October 2023. He succeeds Mark Egerton as CEO, who retired after 18 years in the role. 

With a proven track record in both small molecules and biologics, Thierry is a seasoned executive with over 23 years of experience in the pharmaceutical and CDMO services industry. Thierry has held various senior leadership roles, including as CEO of ABL Inc., CEO of Minakem, President of the Synthesis business unit at Novasep, and Global Head of Business Development at Lonza.